{"filings":[{"id":2310197,"accession_number":"0001193125-26-354738","cik":1643303,"company_name":"Nano Dimension Ltd.","ticker":"NNDM","form_type":"8-K","filed_at":"2026-08-18T12:00:15+00:00","items":["5.02","7.01"],"status":"ready","headline":"Nano Dimension adds Nadav Kidron to board; Infinite Epigenetics exclusivity lapses without deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nadav Kidron appointed to Nano Dimension board as Class II independent director, effective Aug 16, 2026; joins Audit and Compensation committees.","Kidron is CEO of Oramed Pharmaceuticals (ORMP) since 2006; also director at Lifeward (LFWD) and Alpha Tau (DRTS).","30-day exclusivity period under non-binding term sheet with Infinite Epigenetics expired July 15, 2026; no definitive agreement reached.","As of Aug 16, 2026, parties have not reached agreement on definitive terms; no further details disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":351496837.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2105813,"accession_number":"0001193125-26-337947","cik":1643303,"company_name":"Nano Dimension Ltd.","ticker":"NNDM","form_type":"8-K","filed_at":"2026-08-06T20:05:19+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nano Dimension Q2 revenue up 12% to $29M; sells MarkForged to Stratasys","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $29.0M (+12.1% YoY); gross margin 45.9% vs 27.3% YoY.","Net loss from continuing ops $6.8M vs $11.4M loss YoY; adjusted EBITDA loss $9.6M vs $16.7M.","Agreed to sell MarkForged to Stratasys; transaction expected to close H2 2026.","Completed sale of AME and Fabrica product lines; annual cash burn reduction of ~$25M targeted.","Cash and equivalents $433.3M as of June 30, 2026, vs $441.6M at March 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":351496837.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1777236,"accession_number":"0001193125-26-310479","cik":1643303,"company_name":"Nano Dimension Ltd.","ticker":"NNDM","form_type":"8-K","filed_at":"2026-07-21T20:56:32+00:00","items":["1.01","5.01","5.02","5.07","8.01","9.01"],"status":"ready","headline":"Nano Dimension settles activist dispute; CEO Stehlin and three other directors resign, three new directors appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Settlement with Murchinson cancels July 31 EGM; four directors resign including CEO David Stehlin.","Three Murchinson-nominated directors appointed: Fruchthandler, Rozenbaum, Tarlow.","Moshe Rozenbaum appointed Interim CEO effective July 21.","Change in control of company occurred on July 17.","Mutual release of claims and non-disparagement provisions included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":351496837.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1775198,"accession_number":"0001193125-26-310285","cik":1643303,"company_name":"Nano Dimension Ltd.","ticker":"NNDM","form_type":"8-K","filed_at":"2026-07-21T20:05:15+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nano Dimension terminates HQ lease, expects $25M net cash savings through 2031","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement to terminate corporate headquarters lease effective Dec 31, 2026; lease originally from MarkForged (2021) expiring 2031.","Eliminates ~$38M in future lease costs; termination payment of ~$13M yields ~$25M cumulative net cash savings.","Previously disclosed sale of MarkForged expected to reduce annualized cash burn by ~$15M, including ~$7.5M lease savings.","Management emphasizes disciplined capital allocation and continued focus on streamlining operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":351496837.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1111041,"accession_number":"0001104659-26-075126","cik":1643303,"company_name":"Nano Dimension Ltd.","ticker":"NNDM","form_type":"8-K","filed_at":"2026-06-17T20:05:32+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nano Dimension provides update on proposed Infinite Epigenetics acquisition, values company at net cash plus 20% premium","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Infinite Epigenetics is a commercial diagnostics platform with CLIA-certified lab, >120K samples, and >7,500 healthcare providers.","Deal values Nano at net cash plus 20% premium; capital to accelerate commercialization and biological AI platform development.","Nano responds to Murchinson Ltd. criticisms, highlighting board's rigorous review and alignment with shareholder interests.","Infinite's AI platform uses proprietary DNA methylation data (one of world's largest private datasets), targeting >$90B chronic disease market.","No transaction-driven compensation for Nano board; shareholders will vote on definitive agreement once finalized."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":351496837.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1038876,"accession_number":"0001104659-26-073776","cik":1643303,"company_name":"Nano Dimension Ltd.","ticker":"NNDM","form_type":"8-K","filed_at":"2026-06-15T11:48:12+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nano Dimension signs non-binding term sheet to acquire Infinite Epigenetics for $890M stock consideration","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Infinite valued at $890M; Nano valuation based on net cash plus 20% premium plus ~$20M for Essemtec.","Post-closing, Infinite shareholders to own majority; if >55%, they designate 5 of 7 board seats.","Nano will spin off legacy assets via CVR to pre-closing Nano shareholders.","Term sheet includes 30-day exclusivity; no definitive agreement yet.","Nano to reimburse Infinite up to $3M expenses if definitive deal not signed by EGM date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":351496837.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1000556,"accession_number":"0000930413-26-001844","cik":1643303,"company_name":"Nano Dimension Ltd.","ticker":"NNDM","form_type":"8-K","filed_at":"2026-06-11T20:20:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nano Dimension faces activist-led EGM; board backs only two of six proposals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Activist group (Murchinson, Nomis Bay, BPY, Boothbay funds, Oramed) demands EGM on July 31, 2026 in Waltham, MA.","Board recommends FOR: continuation of strategic alternatives review (Prop 1) and board declassification (Prop 2).","Board recommends AGAINST: adding new Articles 71/72, removing three directors, electing three new directors (Props 3-6).","Director Phillip Borenstein dissents from board's recommendations on Proposals 1 and 3-6."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":351496837.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":677036,"accession_number":"0001193125-26-240397","cik":1643303,"company_name":"Nano Dimension Ltd.","ticker":"NNDM","form_type":"8-K","filed_at":"2026-05-27T10:30:16+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nano Dimension sells MarkForged to Stratasys for $42.5M cash, reduces annual burn by $15M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Nano Dimension sells MarkForged subsidiary to Stratasys (SSYS) for $42.5M in cash.","Transaction expected to close in second half of 2026, subject to customary conditions.","Deal projected to reduce Nano's annualized cash burn by approximately $15M.","Nano retains Markforged Metal Binder Jetting product line after the sale.","Sale advances Phase 2 of three-phase strategic plan; Phase 3 discussions progressing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":351496837.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":649876,"accession_number":"0001104659-26-066023","cik":1643303,"company_name":"Nano Dimension Ltd.","ticker":"NNDM","form_type":"8-K","filed_at":"2026-05-26T12:12:47+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nano Dimension board rejects Murchinson’s bid to replace three directors; strategic review continues","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Murchinson filed an amended Schedule 13D, seeking to replace three of five directors, including two it previously nominated and the CEO.","Board rejects the move, stating Murchinson seeks control without paying a premium or presenting a value-creation plan.","Director Andy Sriubas said he will not serve on a board controlled by Murchinson; director Phillip Borenstein disagrees with the letter.","Board invited Murchinson founder Marc Bistricer to join the board under a cooperation agreement; he never responded.","Strategic alternatives review process is ongoing and expected to conclude in the near future to maximize shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":351496837.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94335,"accession_number":"0001193125-26-211866","cik":1643303,"company_name":"Nano Dimension Ltd.","ticker":"NNDM","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nano Dimension Q1 net loss $69.7M (incl. $40.4M impairment); revenue up 106% to $29.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $29.7M (+106% YoY); adjusted gross margin 45.9% vs. 43.3%.","Net loss $69.7M; adjusted EBITDA loss $12.5M; cash $441.6M at March 31, 2026.","Annualized cash burn to be reduced by ~$10M through recent strategic actions.","Full-year 2026 guidance suspended as strategic alternatives process accelerates.","Company executing three-phase plan to maximize shareholder value in 2026+."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":29725000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":351496837.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94334,"accession_number":"0001193125-26-197479","cik":1643303,"company_name":"Nano Dimension Ltd.","ticker":"NNDM","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nano Dimension updates on strategic review; sold AME and Fabrica lines on April 6","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Guggenheim and Houlihan Lokey engaged to evaluate monetization of product lines and financial resources.","Alternatives include strategic merger, reverse merger, or other transactions to maximize shareholder value.","Previously announced April 6 sale of AME and Fabrica product lines to Inspira Technologies.","Company actively discussing multiple potential counterparties under various transaction structures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":351496837.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94333,"accession_number":"0001193125-26-142948","cik":1643303,"company_name":"Nano Dimension Ltd.","ticker":"NNDM","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nano Dimension sells AME & Fabrica product lines to Inspira for up to $12.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration up to $12.5M: $2.0M cash upfront, up to $10.5M deferred based on 12-month performance.","Inspira assumes operational control immediately; transaction subject to customary regulatory approvals.","Expected to reduce annualized cash burn by approximately $10M, strengthening liquidity.","CEO states sale is first step in strategic alternatives review to maximize shareholder value.","Company will update 2026 financial guidance on Q1 2026 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":351496837.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106617,"accession_number":"0001193125-26-134468","cik":1643303,"company_name":"Nano Dimension Ltd.","ticker":"NNDM","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nano Dimension Q4 revenue up 142% to $35.3M; strategic review on track for Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 revenue $102.4M (+77.3% YoY); Q4 revenue $35.3M (+142.4% YoY).","Q4 GAAP gross margin 37.7% (up from 32.9%); adjusted gross margin 49.7% (up from 36.3%).","Q4 net loss from continuing ops $33.9M (wider from $9.3M); adjusted EBITDA loss $9.8M (improved from $18.9M).","Cash, equivalents, deposits and marketable securities $459.6M at Dec 31 2025; $19.8M used for share repurchases in Q4.","Company advancing strategic alternatives review with path forward expected in Q2 2026; FY2026 guidance issued."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":29725000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":351496837.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106616,"accession_number":"0001104659-26-009481","cik":1643303,"company_name":"Nano Dimension Ltd.","ticker":"NNDM","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["1.01","3.03","8.01","9.01"],"status":"ready","headline":"Nano Dimension adopts limited-duration rights plan with 9.99% trigger, expires Feb 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rights plan triggers if any person acquires 9.99%+ of ordinary shares without board approval.","Each right allows holder to buy one ADS for $0.01 once exercisable; rights issued for ADSs held on Feb 13, 2026.","Rights expire on February 1, 2027; board may redeem or exchange rights under certain conditions.","Strategic alternatives review ongoing with advisors Guggenheim Securities and Houlihan Lokey."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":351496837.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106615,"accession_number":"0001104659-26-005254","cik":1643303,"company_name":"Nano Dimension Ltd.","ticker":"NNDM","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nano Dimension Q4 2025 preliminary revenue $35.0-35.5M, above guidance of $31.5-33.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 preliminary revenue $35.0-35.5M, exceeding prior guidance of $31.5-33.5M; strength in defense, aerospace, automotive.","Revenue outperformance driven by Markforged and Essemtec product lines; improved execution and customer relationships.","Strategic alternatives review process continues with Guggenheim and Houlihan Lokey; further updates on upcoming earnings call.","Redomestication to US domestic issuer commenced Jan 1 2026; Form 10-K expected in Q1 2026, completion in H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":102437000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":351496837.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}